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Tumor Promoters and Cocarcinogens in
Tobacco Carcinogenesis
by D. Hoffmann,* S. S. Hecht,* and E. L. Wynder*
Cigarette smoke induces carcinoma of the larynx in Syrian golden hamsters and is active as a tu-
mor promoter in hamsters pretreated with a low dose of a PAH, nitrosamine, or nitrosamide. These
tumorigenic effects are only observed with total smoke, but not with the gas phase alone. This dem-
onstrates that the tumorigenic agents reside primarily in the particulate phase. According to frac-
tionation experiments, a number of four- and five-ring aromatic hydrocarbons serve as the major tu-
mor initiators in tobacco smoke. Tumor promoters reside primarily in weakly polaric neutral subfrac-
tions and in the weakly acidic portion of the particulate matter and include certain unsaturated hy-
drocarbons and phenolic compounds. Cocarcinogenic activity is a characteristic feature of tobacco
smoke and its particulates. Among the cocarcinogens formed during combustion are catechols and
certain nontumorigenic aromatic hydrocarbons and terpenes. Nicotine may also serve as a cocarcin-
ogen as is indicated by preliminary data. The action of tumor promoters and cocarcinogens in
tobacco carcinogenesis, the precursors for tobacco smoke promoters and cocarcinogens, and meth-
ods for their reduction in smoke are discussed.
Introduction
Epidemiological studies have established a causal
relationship of cigarette smoking with cancer of the
larynx and of the lung as well as an association of
cigarette, cigar and pipe smoking with cancer of the
oral cavity, pharynx, larynx and esophagus. It has
also been shown that cigarette smokers have an
increased risk for cancer of the pancreas, kidney
and urinary bladder (1). Tobacco chewing and snuff
dipping have been associated with cancer of the
mouth (1, 2). The exposure to sidestream smoke as
an indoor air pollutant has recently been incrimi-
nated as a possible risk factor for lung cancer
among nonsmokers (3-5).
All of these observations tend to support the con-
cept that tobacco smoke is a complete carcinogen, a
fact, also borne out by smoke inhalation studies and
by tumor induction with tobacco "tar" in the skin of
mice and rabbits and in the subcutaneous tissues
and trachea of rats (6-8).
In the human setting, there is actually only one
suggestion that tobacco smoking may be a tumor
promoter and/or cocarcinogen and this relates to
the role of tobacco smoking in uranium miners.
Occupational exposure to a-particles from radon and
*Naylor Dana Institute for Disease Prevention, American
Health Foundation, Valhalla, NY 10595.
radon-daughters represents the causative factor for
increased lung cancer risk among uranium miners
(1, 9, 10). This is documented by lung cancer in-
cidence rates of 71 per 100,000 nonsmoking uranium
miners in the U.S. per year. Lung cancer incidence
rates per year for individuals who are not subjected
to the occupational uranium exposure are 11 per
100,000 for nonsmokers and 44 per 100,000 for
heavy cigarette smokers. This contrasts sharply
with the rate of 422 for lung cancer among ciga-
rette-smoking uranium miners (11) (Fig. 1).
The initiator-promoter concept which this obser-
vation in man suggests, regards the relatively low
exposure to a-radiation as the initiator and the long
term exposure to cigarette smoke as the tumor-
promoter phase in a two-stage carcinogenesis
model. In fact, studies in experimental tobacco
carcinogenesis confirm that the tumor formation
occurs as a multistep process wherein different
tobacco and smoke constituents play different roles.
It is the purpose of this review to discuss labora-
tory studies which have sought to define these
tobacco carcinogens as well as their respective roles
in the formation of tumors.
Inhalation Experiments
Successful assays for tumorigenic activity of in-
haled tobacco smoke were developed only afterF2OFFMANN, HECHTAND WYNDER
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FIGURE 1. Respiratory cancer rates among uranium miners
by cigarette usage and radiation exposure compared with
rates among nonminers. Data of Archer et al. (11).
FIGURE 2. The Hamburg II smoke inhalation device for
hamsters.
many years of searching for a suitable model. Toxic-
ity of cigarette smoke and the anatomical nasal
features of rodents who were the most accessible
and affordable test objects, presented barriers to
the successful induction of tumors in the respiratory
system. However, the Syrian golden hamster has
finally emerged as the most suitable model (2, 3),
although Nettesheim et al. have recently also
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FIGURE 3. Dissection pattern of the respiratory tract for
determining localized smoke particulate exposure of ham-
sters by measuring radioactive deposites from inhaled (1C)
dotriacontane-labeled cigarette smoke. From Mohr and
Reznik (7).
succeeded with rats (4). The hamsters are exposed
to diluted cigarette smoke (1:15) in tubular com-
partments of a smoking device shown in Figure 2
(15). Each exposure is 10 minutes once, twice or
three times daily, five times per week, for the
duration of the hamsters' lifetime. In these groups
of 80 hamsters each (7), 11.3, 30 and 30.6% of the
animals developed pre- invasive carcinoma of the
upper larynx (Fig. 3) Larynx tumors were not
observed in the control groups, nor in hamsters
exposed only to the gaseous phase of tobacco
smoke. Trachea and bronchi of the animals were
free of neoplasms.
Utilizing this experimental design, we attempted
to document the initiator:promoter concept by
sensitizing the hamsters with subthreshold doses of
known carcinogens prior to long-term inhalation
exposure to certain smoke constituents. Application
of 7,12-dimethylbenz(a)anthracene (DMBA) to the
larynx or intratracheal instillation of DMBA once
weekly for 2 weeks was followed by exposure to
air-diluted smoke (7:1) of nonfilter cigarettes
(1972-1973), 5 days per week (16). Equal-sized
groups received either DMBA or smoke exposure
and a fourth group served as vehicle control, each
hamster receiving 0.2 mL of a 0.5% saline solution
twice in successive weeks and then being observed.
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FIGURE 4. Epithelial changes in hamster larynx induced by DMBA and smoke exposure, smoke exposure alone, or DMBA alone.
Three hamsters each in Groups I and II and two hamsters each in Groups III and IV were lost due to cannibalism. Data of
Kobayashi et al. (16).
After 48 weeks of inhalation and another 4 weeks
of observation, the animals were killed and
necropsied. Hyperplasia and neoplastic lesions and
tumors developed in the larynx of the hamsters
receiving both DMBA and smoke in significantly
higher incidence, and earlier than in the group
treated by smoke exposure only. In addition, the
DMBA-sensitized hamsters showed also squamous
cell metaplasia of the nasal cavity and papilloma of
the oral cavity as well as pharyngeal papillomas,
thus indicating promoter activities for cigarette
smoke (Fig. 4). Dontenwill et al. (17) had also
measured the effects of treatment with DMBA in
addition to smoke exposure and found that the
numbers of tumors obtained in the oral cavity,
pharynx, esophagus, forestomach and trachea were
significantly increased over the tumor yield induced
by smoke exposure alone.
With 4 mg diethylnitrosamine (DENA) as initia-
tor we had exposed Syrian golden hamsters to the
smoke of 10 cigarettes daily in a 72 liter inhalation
chamber for 6 months (15). The same device was
also used to measure the effects of the gaseous
smoke phase and the effects of a vaporized
aldehyde-acid mixture corresponding to ratios of
smoke aldehydes and acids on DENA-induced
respiratory neoplasms (Fig. 5). Although the set-up
did not exclude artifacts during aging of the smoke,
this experiment strengthened the hypothesis that
total smoke as well as gaseous smoke constituents
increase DENA-induced tumor formation in the
hamster trachea (Table 1).
Nitrosamines as initiators were also used by Don-
tenwill et al. (17, 18), Wehner et al. (19) and by
Karbe and Koster (20) in essentially similar smoke
inhalation assays with the Syrian golden hamster.
Table 2 summarizes the principal alterations ob-
served in major studies by hamster pretreatment
with DMBA, diethylnitrosamine (DENA), N-methyl-
N-nitroso-urea (NMU) and asbestos (15,17-21). All of
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FIGURE 5. Multiple benign papillomas of the trachea of a Syrian golden hamster given 4 mg of DENA and exposed to an admix-
ture of smoke acids and aldehydes for 6 months. HE; x 15.
Table 1. Passive inhalation of aged cigarette smoke
by Syrian golden hamsters.a
Exposure, monthsb
1 3 4 5 6
1 4mgDENA + 1 2 6
cigarette smoke 12 9 7 5 0
1 4 17
2 4mgDENA+ 8
aldehydes 12 12 12 12 0
20
9
3 4mgDENA + acidsc 12 12 12 12 0
23
4 4mgDENA+ 11
aldehydes + acidsc 12 12 12 12 0
34
5 4mgDENA+ 6
methyl nitrite 12 12 12 12 0
21
6 Methyl nitritec 10 9 9 9 7d
3
7 4mgDENA 12 10 8 6 0
4
a Data ofHoffmann et al. (15).
b Upper number in each column denotes number of hamsters
with tracheal papillomas, number in center of column =
surviving hamsters and lower number = total number of
tracheal papillomas.
c In concentrations as in 15 min aged smoke of 10 cigarettes.
d Terminated after 10 months, no tumors were observed.
these studies except one with DENA by Wehner et
al. (21) indicate the tumor promoter potential of
cigarette smoke, whereby the severity of histopath-
ologic grading of lesions appears to be related to
the initiator potential of the pretreatment as well as
to the dose and duration oftobacco smoke exposure.
Studies by Karbe and Koster have shown that
smoke exposure by inhalation increased the in-
cidence of malignant tumors in NMU-initiated
hamsters about 4-fold (20).
The observations that respiratory tumor develop-
ment is largely dose-dependent on the promoter, in
this case tobacco smoke, provide a plausible ex-
planation for the fact that the risk of lung cancer in
ex-smokers declines progressively when the pro-
moter insult ceases (22, 23) as was discussed (24) by
Wynder during this symposium (Fig. 6).
Tumor-promoting effects of tobacco smoke in
hamsters who were pretreated with tobacco-specific
N-nitrosamines (TSNA) have not been established.
It would be of major importance to study such
effects because TSNA are formed from tobacco
alkaloids, occur in smoke at levels up to 8 S*g per
cigarette and are organ-specific carcinogens (25)
(Table 3).
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Table 2. Principle alterations in animals exposed to DMBA,
DENA, and asbestos in addition to smoke exposure compared to
their single-substance controls.
Treatment Principal alterations Reference
DENA + smoke Increase in incidence of pap- (17)
illomas in the trachea, (15)
bronchi, and lower region
of the larynx
NMU + smoke Increase in epidermoid car- (20)
cinoma (grade 5) in the
larynx and increase in
precancerous lesions
(grade 4) in larynx and
pharynx
DMBA + smoke Increase in incidence of tu- (17)
mors in the oral cavity, (16)
pharynx, esophagus,
stomach, trachea, liver
and ovaries
Asbestos + smoke Development of laryngeal (17)
tumors. Absence of tu- (19)
mors in the bronchi, tra-
chea and pharynx
Studies with the Particulate Phase
The gaseous phase of tobacco smoke does not by
itself induce tumors of the respiratory tract in
laboratory animals (8, 17). Thus, it may be deduced
that the major carcinogenic activity resides in the
particulate phase, more commonly known as "tar."
Benign and malignant tumors have been induced
with tobacco tar in the skin and ear
When efforts were made to pinpoint the carcino-
gens in the tar by fractionations, bioassays ..on
mouse skin revealed that the observed tumorigenic
activities were composite effects of the intricate
mixture of compounds which constitutes cigarette
smoke particulates. Chemical identification of such
compounds has led to the knowledge that certain
polynuclear aromatic hydrocarbons are the major
tumor initiators, but that the neutral and weakly
acidic fractions of tar contain various types of
cocarcinogens and tumor promoters (Fig. 7) (26, 27).
It is also important that the smoke particulates as a
whole have dose-related promoting effects on
DMBA- initiated mouse skin (Fig. 8).
CASES: CONTROLS
S, 0.8
o0.7 ~~~~43:121
3 6
2 a
0 Q5 _ 35:147
PRESENT 43-6 7-lO 11-15121+ SSO2:10
z
9 036
252
0~~~~~~~~~~~~~~~~:0
YEARS SINCE QUIT SMOKING
FIGURE 6. Decline of lung cancer in ex-smokers. Wynder and
Stellman, (22).
Neutral Portion
A few years ago, we reported that the phenan-
threne subfraction and the polynuclear aromatic hy-
drocarbon (PAH) subfractions of the neutral portion
of cigarette "tar" are active as cocarcinogens when
applied to mouse skin, together with 0.003% BaP
(26, 27, 36, 37). Three and four-ring PAH are known
cocarcinogens rather than active tumor initiators. It
became, therefore, an important task to determine
them individually and to examine whether the
neutral portion contained yet other cocarcinogens,
since PAH are primarily pyrosynthesized during
the incomplete combustion of tobacco by the same
mechanism.
We approached the determination of cocarcino-
genic agents by fractionation of cigarette "tar" with
several distribution steps and column chromatog-
raphy. This resulted in five neutral subfractions
(Fig. 9). The two PAH- containing subfractions were
Table 3. Tobacco specificN-nitrosamines in tobacco products.a
Tobacco, Chewing tobacco Cigarette smoke, Cigar smoke,
Nitrosamines ppm or snuff, ppm lAg/cigarette pg/cigar
N'-Nitrosonornicotine 0.2-45 3.5 -77 0.2 -3.7 3.2-5.5
NNKb 0.1-35 0.8 - 4.7 0.12-0.44 1.9-4.2
N'-Nitrosoanabasine 0.0-0.01 0.04- 1.9 0.0 -0.15 n.d.C
N'-Nitrosoanatabine 0.6-13 0.8 -44 0.15-4.6 1.7-1.9
a Data ofHoffmann et al., (15).
b NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Not determined.
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FIGURE 7. Fractionation of tobacco smoke particulates and relative carcinogenic and promoter activities of major fractions. Data
of Wynder and Hoffmann (8).
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FIGURE 8. Tumor-promoting activities of cigai
condensate. Initiator: 150 g dimethylbenz(;
(DMBA). Promoters: 50% solutions ofsmoke co
standard cigarette or of cigarettes made of sti
tested per group. 33% solutions of both test ma
tested on 30 mice per group. Use of 150 g DMB
with acetone as promoter yielded no tumors
Data ofWynder and Hoffmann (37).
+50%STANDARD further separated into two portions at - 70°C: CONDENSATE acetone-solubles (PAH) and the acetone-insolubles
+3%STANDARD (free of PAH). All seven neutral subfractions were
CONDENSATE bioassayed on mouse skin for their cocarcinogenic
activity together with 0.003% BaP. (The fractions
were applied in proportions relative to their
amounts in undiluted tar). None of the fractions
were active as complete carcinogens in the chosen
+50%"STEM" concentrations, however, the acetone-solubles and
CONDENSATE acetone-insolubles of the alkylnaphthalene and PAH
subfractions were active as cocarcinogens (Fig. 10).
In-depth chemical analytical studies of the ace-
tone-solubles of the alkylnaphthalene fraction re-
+33%NSTEM" vealed the presence of methyl- and dimethylnaph-
CONDENSATE thalenes, methyl- and dimethylbiphenyls, methyl-
and dimethylfluorenes, methylanthracenes, and DIBA methylphenanthrenes.
VATION The insolubles of the PAH subfraction yielded as
rette smoke major compounds solanone, phytone, 2-hexadeca-
a)anthracene none, 2-heptadecanone, 3-heptadecanone, 2-octadeca-
ndensates of none, 2-nonadecanone, 3-nonadecanone, 2-eicosanone
ems; 90 mice and 3-docosanone. It is important that these long- aterials were chain methyl and ethyl ketones and/or their
A
in 50 mice precursors are plant-specific and are found in these
concentrations only in tobacco and the resulting
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FIGURE 9. Fractionation of cigarette tar for bioassays to determine cocarcinogenic activity of neutral subfractions. Data of
American Health Foundation.
smoke. They account for 0.5-1.5% of the cigarette
smoke condensate. Their individual cocarcinogenic
potential needs to be determined.
Weakly Acidic Portion
Constituents of the weakly acidic fraction of to-
bacco tar were shown to act as tumor promoters or
as cocarcinogens respectively (8, 27-29, 37). Coap-
plication of HPLC subfractions of the weakly acidic
portion of tar with 0.003% BaP on mouse skin
identified catechol as a major component of
materials with cocarcinogenic activity (27), thus
confirming studies by Van Duuren et al. (28).
However, other weakly acidic compounds, though of
lesser activity, contribute to the cocarcinogenic
potential of the weakly acidic portion (Fig. 11). The
verification of dose responses for catechol with BaP
and the testing of other constituents of the active
subfractions are still in progress.
It is of particular interest that the cocarcinogenic
activities of active subfractions in these tests was
expressed in terms of increased percentage of
tumor-bearing animals as well as in terms of total
tumor yield (Table 4). This is thus a true additive
effect rather than merely an acceleration of tumor
development as was observed with certain neutral
smoke constituents. Tumor promotion in the
classical sense by weakly acidic smoke constituents
was demonstrated particularly for phenol in our
studies on mouse skin with BaP as initiator (30), al-
though Van Duuren found partial inhibition of BaP
activity by phenol (31).
In view of such contradictory evidence and be-
cause of the fact that tumor-promoting activity and
cocarcinogenic activity are not necessarily always
correlated, further studies on metabolic processes
during initiation and promotion, respectively during
cocarcinogen application need to be undertaken.
Nicotine as a Possible
Cocarcinogen
Discussion of cocarcinogenic activities of tobacco
smoke would hardly be complete without alluding
to the role of nicotine, especially since Bock and
collaborators found that tobacco extracts had tumor
promoting activity on DMBA-initiated -mouse skin.
However, this activity requires the concurrent
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FIGURE 10. Bioassay data on mouse skin (ICR9) from tests for cocarcinogenic activity of neutral subfractions of tobacco smoke
condensate (30 mice per group). AIK N = neutral alkanes, PAH = polynuclear aromatic hydrocarbons, BaP = benzo(a)pyrene,
ppt = precipitate, sol = solubles. Data ofAmerican Health Foundation.
presence of two agents, one of large molecular
weight (LM), insoluble in organic solvents, and the
other of small molecular weight (SM), soluble in
organic solvents (32). It is suggested that the SM
agent could be nicotine (33) while the LM fraction
with the highest activity may consist of tobacco leaf
pigments.
Model studies by Bock (34) on enhancement of
BaP-TPA carcinogenesis by nicotine showed that
such an effect was not due to the alkaloid's specific
involvement in either initiation or promotion. The
enhancement of carcinogenesis was also not a
consequence of the metabolic conversion of nicotine
to either cotinine or NNO (Table 5). Thus, Bock
concluded "if metabolism of nicotine is critical for its
activity, some other as yet unidentified metabolite
must be involved."
Bock's studies on nicotine as a copromoter did
point to a factor which has proven to be critical in a
number of other investigations of cocarcinogenic
effects, namely the relative ratio of the stimulant to
the initiating carcinogen. In coapplication, variation
of this relative ratio can produce effects ranging
from enhancement to inhibition.
We have seen such effects in studies with benzo-
(a)pyrene in coapplication with various molecular
ratios of phenanthrene, pyrene and fluoranthene
(35).
Furthermore, the concentration, sequence and
frequency of application are critical in simple
models but more so in complex admixtures (36, 37).
Bock has shown that in an initiation-promotion pro-
tocol nicotine did not enhance the activity of TPA
with an initiator dose of 125M.g DMBA.
Summary
The study of tumor promotion and cocarcinogenic
effects in tobacco carcinogenesis has pointed to
several classes of compounds which enhance the
carcinogenic potential of tumor initiators that are
germane to tobacco as well as to other known
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FIGURE 11. Subfractionation of major subfractions II and III of the weakly acidic fraction of smoke condensates. Data of Hecht et al.
(29).
Table 4. Cocarcinogenicity ofsubfractions of the weakly acidic fractiona b
Animals with
Mean Animals Squamous
Effective latency surviving Skin cell Skin
no. of period, 52 wk, tumors, carcinoma tumors/
BP and subfractions animals wk 0/0 0/0C (skin), % mouse
BP (0.003% in acetone) 28 41.0 90 14 11 0.1
BP (0.003% in ethanol) 30 39.5 87 3 3 0.2
BP (0.003%) + subfraction A (0.25%) 30 41.7 57 73* 64* 1.4
BP (0.003%) + subfraction B (0.16%) 30 48.2 80 60* 47* 0.9
BP(0.003%) + subfraction C (0.014%) 29 43.9 73 52* 38+ 0.5
BP (0.003%) + subfraction D (0.014%) 30 43.4 83 33 27 0.3
BP (0.003%) + subfraction E (0.16%) 30 42.5 83 10 3 0.1
BP(0.003%) + subfraction F (1.2%) 29 43.3 47 76* 66* 2.1
BP(0.003%) + subfraction G (0.25%) 30 47.1 80 47* 33+ 0.5
BP (0.003%) + subfraction H (0.36%) 30 43.6 67 73* 70* 1.4
BP (0.003%) + subfraction I (0.19%) 28 43.5 73 61* 50* 0.9
BP(0.003%) + subfraction J (0.51%) 30 46.0 83 23 + 7 0.3
a Data of Hecht, et al. (29).
b Each group consisted of 30 Ha:ICR female Swiss mice. Solutions were applied five times weekly for 52 wk. Subfractions A-D and
F-I were applied in acetone, Subfractions E and J were applied in ethanol.
c One skin tumor was observed in the acetone control group, and no skin tumors were observed in the groups treated with ethanol
or with each fraction without BP.
* Significant,p<0.01.
+ Significant,p<0.05.
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Table 5. Effect of nicotine metabolites on carcinogenic activity of B[a]P-TPA in acetonea.b
Mice with skin Number Comparison with
Number tumors of B[a]P-TPA alone
Number of mice mice with
Test solution of mice at riskc Number % skin cancer X2 p
B[a]P-TPA aloned 75 75 37 49 22 - -
B[a]P-TPA + 2.5 mg/mL nicotine 50 50 39 78 19 42 <0.001
B[a]P-TPA + 5mg/mL nicotine 50 38 31 82 15 68 <0.001
B[a]P-TPA + 2.5 mg/mL cotinine 45 45 26 58 18 1.8 N.s.Y
B[a]P-TPA + 5mg/mL cotinine 45 45 29 64 18 4.6 0.03
B[a]P-TPA + 2.5 mg/mL NNO 45 45 10 22 8 13.8 <0.001
B[a]P-TPA + 5mg/mL NNO 45 45 12 27 10 10.2 <0.01
a Data ofBock et al. (32).
b B(a)P = benzo(a)pyrene; TPA= tetradecanoylphorbol acetate.
I Number alive at 10 weeks when the first tumor appeared.
d 10pg B[a]P plus 0.6,g TPA per mL; 0.2 mL applied 10 times a week.
e Not significant.
tumor initiators. Among these are noncarcinogenic
polycyclic aromatic hydrocarbons and their alkylat-
ed derivatives, acids and aldehydes of the gaseous
phase of smoke, catechols and phenols and, possibly
nicotine. These compounds enhance carcinogenic
processes induced by polynuclear aromatic hydro-
carbons, N-nitrosamines and likely other as yet uni-
dentified tumor initiators.
Delineation of the mechanisms that lead to spe-
cific activities of the various classes of cocarcino-
genic or tumor promoting compounds would indi-
cate possibilities for chemopreventive approaches to
tobacco carcinogenesis.
In practical terms, tobacco carcinogenesis contin-
ues to be most effectively reduced by diminishing
the levels of initiators, promoters and cocarcinogens
in smoke, since the carcinogenic as well as tumor
promoting effects of the smoke particulates are
clearly dose-related.
These studies were supported by National Cancer Institute
Grant 1 P01 CA 29580.
REFERENCES
1. U.S. Department of Health, Education and Welfare. U.S.
Smoking and Health. A Report of the Surgeon General.
DHEW Publ. No. (PHS) 79-50066, Washington, DC, (1979),
1136p.
2. Winn, D. M., Blot, W. J., Shy, M. C., Pickle, L. W., Toledo,
M. A., and Fraumeni, J. F., Jr. Snuff dipping and oral can-
cer among women in the Southern United States. New
Engl. J. Med. 304: 745-749 (1981).
3. Hirayama, T. Non-smoking wives of heavy smokers have
higher risk of lung cancer. A study from Japan. Brit. Med.
J. 282: 183-185 (1981).
4. Trichopoulos, D., Kalandidi, A., Sparros, L., and MacMa-
hon, B. Lung cancer and passive smoking. Int. J. Cancer
27: 1-4 (1981).
5. Brunnemann, K. D., and Hoffman, D. Chemical studies on
tobacco smoke LIX. Analysis of volatile nitrosamines in
tobacco smoke and polluted indoor environments. In: En-
vironmental Aspects of N-Nitroso Compounds (E. A.
Walker, M. Castegnaro, L. Griciute, and R. E. Lyle, Eds.)
IARC Publication 19, IARC, Lyon, 1978, pp. 343-356.
6. Hecht, S. S., and Wynder, E. L. (Eds.) Lung Cancer Work-
shops on the Biology of Human Cancer. U.I.C.C. Techn.
Report Ser. 28, Rept. 3, Geneva, 1977.
7. Mohr, U., and Reznik, G. Tobacco carcinogenesis. In:
Lung Biology in Health and Disease, Vol. 10, Pathogenesis
and Therapy of Lung Cancer (C. C. Harris, Ed.), Marcel
Dekker, New York 1978, pp. 263-367.
8. Wynder, E. L. and Hoffman, D. Tobacco and Tobacco
Smoke. Studies in Experimental Carcinogenesis. Aca-
demic Press, New York, 1967.
9. Hoffmann, D., and Wynder, E. L. Smoking and occupa-
tional cancers. Prev. Med. 5: 245-261 (1976).
10. Donaldson, A. W. The epidemiology of lung cancer among
uranium miners. Health Physics 16: 563-569 (1969).
11. Archer, V. E., Wagoner, J. K., Lundin, F. E., Jr. Uranium
mining and cigarette smoking effects on man. J. Occup.
Med. 15: 204-211 (1973).
12. Dontenwill, W., and Wiebecke, B. Tracheal and pulmo-
nary alterations following the inhalation of cigarette
smoke by golden hamsters. In: Lung Tumors in Animals
(L. Severi, ed.), Univ. Perugia, Italy, 1966, pp. 519-526.
13. Bernfeld, P., Homburger, F., Soto, E., and Pai, K. J. Ciga-
rette smoke inhalation studies in inbred Syrian golden
hamsters. J. Natl. Cancer Inst. 63: 675-689 (1979).
14. Dalbey, W. E., Nettesheim, P., Griesemer, R., Caton,
J. E., and Guerin, M. R. Chronic inhalation of cigarette
smoke by F-344 rats. J. Natl. Cancer Inst. 64: 383-390
(1980).
15. Hoffman, D., Rivenson, A., Hecht, S. S., Hilfrich, J., Koba-
yashi, N., and Wynder, E. L. Model studies in tobacco
carcinogenesis with the Syrian golden hamster. Progr.
Exptl. Tumor Res. 24: 370-390 (1979).
16. Kobayashi, N., Hoffman, D., and Wynder, E. L. A study of
tobacco carcinogenesis. XII. Epithelial changes induced in
the upper respiratory tracts of Syrian golden hamsters by
cigarette smoke. J. Natl. Cancer Inst. 53: 1085- 1089
(1974).
17. Dontenwill, W., Chevalier, H. J., Harke, H. P., Lafrenz,
U., Reckzeh, G., and Schneider, B. Investigations on the
effects of chronic cigarette smoke inhalation in Syrian gol-
den hamsters. J. Natl. Cancer Inst. 51: 1781-1832 (1973).TOBACCO CARCINOGENESIS 257
18. Dontenwill, W. P. Effect of chronic cigarette smoke inha-
lation on Syrian golden hamsters. In: Experimental Lung
Cancer (E. Karbe and J. F. Parke, Eds.), Springer Verlag,
New York, 1974, pp. 331-382.
19. Wehner, A. P., Busch, R. H., Olson, R. J., and Craig, D. K.
Chronic inhalation of asbestos and cigarette smoke by
hamsters. Environ. Res. 10: 368-383 (1975).
20. Karbe, E., and Koster, K. Carcinogenicity of inhaled ciga-
rette smoke in the NMU-pretreated hamster larynx. In:
Experimental Lung Cancer (E. Karbe and J. F. Parke,
Eds.), Springer Verlag, New York, 1974, pp. 369-382.
21. Wehner, A. P., Busch, R. H., and Olson, R. J. Effects of di-
ethylnitrosamine and cigarette smoke on hamsters. J.
Natl. Cancer Inst. 56: 749-756 (1976).
22. Wynder, E. L. and Stellman, S. D. Comparative epidemi-
ology of tobacco-related cancers. Cancer 37: 4608-4622
(1977).
23. Hammond, E. C. Smoking habits and air pollution in rela-
tion to lung cancer. In: Environmental Factors in Respira-
tory Disease (D. H. K. Lee, Ed.) Fogarty International
Center Proceedings No. 11, Academic Press, New York,
1972, pp. 177-198.
24. Wynder, E. L. Tumor enhancers: under estimated factors
in the epidemiology of lifestyle-associated cancers. En-
viron. Health Perspect. 50: 15-21 (1983).
25. Hoffmann, D., Castonguay, A., Rivenson, A., and Hecht,
S. S. Comparative carcinogenicity and metabolism of 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N'-nitro-
sonornicotine in Syrian golden hamsters. Cancer Res. 41:
2386-2393 (1981).
26. Schmeltz, I., Tosk, J., Hilfrich, J., Hirota, N., Hoffman, D.,
and Wynder, E. L. Bioassays of naphthalene and alkyl-
naphthalenes for co-carcinogenic activity. Relation to to-
bacco carcinogenesis. In: Carcinogenesis. Vol. 3 (P. W.
Jones and R. I. Freudenthal, Eds.), Raven Press, New
York, 1978, pp. 47-60.
27. Hoffmann, D., Schmeltz, I., Hecht, S. S., and Wynder,
E. L. Chemical studies on tobacco smoke. IL. On the iden-
tification of carcinogens, tumor promoters and cocarcino-
gens in tobacco smoke. Proc. Third World Conf. Smoking
and Health. DHEW Publ. No. (NIH) 76-1221, Washington,
DC, 1976 pp. 125-145.
28. Van Duuren, B. C., and Goldschmidt, B. M. Cocarcinogenic
and tumor promoting agents in tobacco carcinogenesis. J.
Natl. Cancer Inst. 56: 1237-1242 (1976).
29. Hecht, S. S., Carmella, S., Mori, H., and Hoffmann, D. A
study of tobacco carcinogenesis. XX. Role of catechol as a
major cocarcinogen in the weekly acidic fraction of smoke
condensate. J. Natl. Cancer Inst. 66: 163-169 (1981).
30. Wynder, E. L., and Hoffmann, D. A study of tobacco carci-
nogenesis. VIII. The role of the acidic fractions as pro-
moters. Cancer 14: 1306-1315 (1961).
31. Van Duuren, B. C., Katz, C., and Goldschmidt, B. M. Co-
carcinogenic agents in tobacco carcinogenesis. J. Natl.
Cancer Inst. 51: 703-705 (1973).
32. Bock. F. G. and Tso, T. C. Chemical and biological identifi-
cation of tumorigenic components of tobacco. In: Smoking
and Health. I. Modifying the Risk for the Smoker (E. L.
Wynder, D. Hoffmann, and G. B. Gori, Eds.), Proceedings
of the 3rd World Conference on Smoking and Health.
DHEW Publ. No. (NIH) 76-1221, 1976, pp. 161-173.
33. Bock, F. G., and Tso, T. C. Tumor promoting activity of
agricultural chemicals. In: Smoking and Health. I. Modi-
fying the Risk for the Smoker (E. L. Wynder, D. Hoffman,
and G. B. Gori, Eds.), Proceedings of the 3rd World Con-
ference on Smoking and Health, DHEW Publ. No. (NIH)
76-1221, 1976, pp. 175-189.
34. Bock, F. G. Cocarcinogenic properties of nicotine. In: A
Safe Cigarette? (G. B. Gori and F. G. Bock, Eds.), Banbury
Rpt. No. 3, Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York, 1980, pp. 129-139.
35. Hoffmann, D., and Wynder, E. L. Studies on gasoline en-
gine exhaust. J. Air Pollution Control Assoc. 13: 322-327
(1963).
36. Hoffman, D., and Wynder, E. L. A study of tobacco carci-
nogenesis. XI. Tumor initiators, tumor accelerators, and
tumor promoting activity of condensate fractions. Cancer
27: 848-864 (1971).
37. Wynder, E. L., and Hoffmann, D. A study of tobacco carci-
nogenesis. X. Tumor promoting activity. Cancer 24:
289-301 (1969).